Entrada Therapeutics' drug for children with Duchenne muscular dystrophy fell well short of analyst expectations ​in an early ...

Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development ...

While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares ...

Muscle weakness in Duchenne muscular dystrophy can lead to symptoms related to mobility, coordination, posture, and breathing, as well as other health effects. Duchenne muscular dystrophy (DMD) is a ...

SPOKANE, Wash. — In the spring of 2023, the Bufus family learned that their sons, Mason and Jack, were both diagnosed with a rare genetic disease, Duchenne Muscular Dystrophy (DMD). DMD is one of the ...

Add Yahoo as a preferred source to see more of our stories on Google. When Conner Curran was first diagnosed with Duchenne muscular dystrophy at age 4, his parents were told there was nothing they ...

The RPD designation is given to therapies targeting serious or life-threatening conditions that primarily affect children. ・(Z)-endoxifen already has an RPD designation for the treatment of Duchenne ...

The Becker muscular dystrophy (BMD) age of onset ranges from 5 to 60 years. However, some sources suggest symptoms usually develop in a person’s teens or early twenties. BMD is a type of recessive ...

Duchenne muscular dystrophy affects one in 3,500 boys worldwide. Despite its prevalence, not much is known about it in our own neighborhoods and communities. Our son Aidan was diagnosed with Duchenne ...

The approval follows fast track, orphan drug, and rare pediatric designations and an original Prescription Drug User Fee Act date of December 21, which the FDA pushed back to March 21 to have more ...

Sarepta Therapeutics said on Tuesday a 16-year-old boy has died due to acute liver failure, months after he received the company's U.S.-approved gene therapy for a rare muscular dystrophy. The patient ...

The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative ...